285 related articles for article (PubMed ID: 15201598)
1. Recent advances in the management of psoriatic arthritis.
Mease PJ
Curr Opin Rheumatol; 2004 Jul; 16(4):366-70. PubMed ID: 15201598
[TBL] [Abstract][Full Text] [Related]
2. Psoriatic arthritis therapy advances.
Mease PJ
Curr Opin Rheumatol; 2005 Jul; 17(4):426-32. PubMed ID: 15956839
[TBL] [Abstract][Full Text] [Related]
3. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics.
Gottlieb A; Korman NJ; Gordon KB; Feldman SR; Lebwohl M; Koo JY; Van Voorhees AS; Elmets CA; Leonardi CL; Beutner KR; Bhushan R; Menter A
J Am Acad Dermatol; 2008 May; 58(5):851-64. PubMed ID: 18423261
[TBL] [Abstract][Full Text] [Related]
4. Emerging drugs for psoriatic arthritis.
Olivieri I; D'Angelo S; Palazzi C; Lubrano E; Leccese P
Expert Opin Emerg Drugs; 2010 Sep; 15(3):399-414. PubMed ID: 20528612
[TBL] [Abstract][Full Text] [Related]
5. TNFalpha therapy in psoriatic arthritis and psoriasis.
Mease P
Ann Rheum Dis; 2004 Jul; 63(7):755-8. PubMed ID: 15194567
[No Abstract] [Full Text] [Related]
6. New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol.
Cauli A; Piga M; Lubrano E; Marchesoni A; Floris A; Mathieu A
J Rheumatol Suppl; 2015 Nov; 93():70-2. PubMed ID: 26523062
[TBL] [Abstract][Full Text] [Related]
7. Management of Psoriatic Arthritis: Traditional Disease-Modifying Rheumatic Agents and Targeted Small Molecules.
Soriano ER
Rheum Dis Clin North Am; 2015 Nov; 41(4):711-22. PubMed ID: 26476228
[TBL] [Abstract][Full Text] [Related]
8. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
Tobin AM; Kirby B
BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217
[TBL] [Abstract][Full Text] [Related]
9. [The role of biological agents in the treatment of psoriatic arthritis, literature review].
Koó E; Brodszky V; Péntek M; Ujfalussy I; Nagy MB; Gulácsi L
Orv Hetil; 2006 Oct; 147(41):1963-70. PubMed ID: 17120686
[TBL] [Abstract][Full Text] [Related]
10. Disease-modifying Antirheumatic Drugs (DMARD) and Combination Therapy of Conventional DMARD in Patients with Spondyloarthritis and Psoriatic Arthritis with Axial Involvement.
Simone D; Nowik M; Gremese E; Ferraccioli GF
J Rheumatol Suppl; 2015 Nov; 93():65-9. PubMed ID: 26523061
[TBL] [Abstract][Full Text] [Related]
11. Novel Therapeutics in Psoriatic Arthritis. What Is in the Pipeline?
Elalouf O; Chandran V
Curr Rheumatol Rep; 2018 May; 20(7):36. PubMed ID: 29846825
[TBL] [Abstract][Full Text] [Related]
12. Psoriatic arthritis: biologics seen as new treatment. More aggressive treatment is recommended for psoriatic arthritis, a severe, progressive form of the disease.
Duke Med Health News; 2012 Apr; 18(4):7. PubMed ID: 22545278
[No Abstract] [Full Text] [Related]
13. Biological agents in psoriatic arthritis.
Kocijan R; Muschitz C; Rech J
Wien Med Wochenschr; 2015 Jan; 165(1-2):36-9. PubMed ID: 25205184
[TBL] [Abstract][Full Text] [Related]
14. Resistant cases of psoriatic arthritis: how to manage them.
Atzeni F; Sarzi-Puttini P; Vena GA
J Rheumatol Suppl; 2009 Aug; 83():73-5. PubMed ID: 19661549
[TBL] [Abstract][Full Text] [Related]
15. Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: a systematic review.
Armstrong AW; Brezinski EA; Follansbee MR; Armstrong EJ
Curr Pharm Des; 2014; 20(4):500-12. PubMed ID: 23565631
[TBL] [Abstract][Full Text] [Related]
16. Disease-modifying antirheumatic drug therapy for psoriatic arthritis.
Salvarani C; Cantini F; Olivieri I
Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S71-5. PubMed ID: 12463452
[TBL] [Abstract][Full Text] [Related]
17. The Role of Tumor Necrosis Factor-α Blockers in Psoriatic Disease. Therapeutic Options in Psoriatic Arthritis.
Addimanda O; Possemato N; Caruso A; Pipitone N; Salvarani C
J Rheumatol Suppl; 2015 Nov; 93():73-8. PubMed ID: 26523063
[TBL] [Abstract][Full Text] [Related]
18. Biologic therapy of psoriatic arthritis.
Gladman DD
Reumatismo; 2007; 59 Suppl 1():85-7. PubMed ID: 17828353
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis.
Cummins E; Asseburg C; Punekar YS; Shore E; Morris J; Briggs A; Fenwick E
Value Health; 2011 Jan; 14(1):15-23. PubMed ID: 21211482
[TBL] [Abstract][Full Text] [Related]
20. Endothelial dysfunction and the effects of TNF inhibitors on the endothelium in psoriasis and psoriatic arthritis: a systematic review.
Brezinski EA; Follansbee MR; Armstrong EJ; Armstrong AW
Curr Pharm Des; 2014; 20(4):513-28. PubMed ID: 23565632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
